antimanic agents

Summary

Summary: Agents that are used to treat bipolar disorders or mania associated with other affective disorders.

Top Publications

  1. ncbi Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
    Andrea Cipriani
    Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Italy
    Lancet 378:1306-15. 2011
  2. ncbi A common mechanism of action for three mood-stabilizing drugs
    Robin S B Williams
    Intracellular Signalling Group, MRC Laboratory for Molecular Cell Biology, University College London, Gower St, London WC1E 6BT, UK
    Nature 417:292-5. 2002
  3. ncbi Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    J Neurosci 24:6578-89. 2004
  4. ncbi Adherence to guidelines by French psychiatrists in their real world of clinical practice
    Ludovic Samalin
    Centre Hospitalier Universitaire, Clermont Ferrand, France
    J Nerv Ment Dis 199:239-43. 2011
  5. ncbi Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians
    Roy H Perlis
    Depression and Bipolar Clinical and Research Programs, Massachusetts General Hospital, Boston, MA 02114, USA
    Curr Med Res Opin 23:467-75. 2007
  6. ncbi Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
    Konstantinos N Fountoulakis
    3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, 6 Odysseos str 1st Parodos Ampelonon str, Pylaia, Thessaloniki, Greece
    Eur Arch Psychiatry Clin Neurosci 262:1-48. 2012
  7. ncbi Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder
    Alessio Squassina
    Department of Neuroscience BB Brodie, University of Cagliari, Cagliari, Italy
    Pharmacogenomics 12:1559-69. 2011
  8. pmc Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder
    M J McCarthy
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
    Genes Brain Behav 10:852-61. 2011
  9. ncbi Pharmacotherapy for the treatment of acute bipolar II depression: current evidence
    Holly A Swartz
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Clin Psychiatry 72:356-66. 2011
  10. ncbi Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis
    Michelle M Sidor
    Department of Psychiatry, University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9070, USA
    J Clin Psychiatry 72:156-67. 2011

Detail Information

Publications260 found, 100 shown here

  1. ncbi Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis
    Andrea Cipriani
    Department of Public Health and Community Medicine, Section of Psychiatry and Clinical Psychology, University of Verona, Italy
    Lancet 378:1306-15. 2011
    ..We did a multiple-treatments meta-analysis, which accounted for both direct and indirect comparisons, to assess the effects of all antimanic drugs...
  2. ncbi A common mechanism of action for three mood-stabilizing drugs
    Robin S B Williams
    Intracellular Signalling Group, MRC Laboratory for Molecular Cell Biology, University College London, Gower St, London WC1E 6BT, UK
    Nature 417:292-5. 2002
    ..Inhibitors of prolyl oligopeptidase reverse the effects of all three drugs on sensory neuron growth cone area and collapse. These results suggest a molecular basis for both bipolar affective disorder and its treatment...
  3. ncbi Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    J Neurosci 24:6578-89. 2004
    ..trafficking regulates synaptic plasticity, effects mediated by signaling cascades, which are targets for antimanic agents. The present studies were undertaken to determine whether two clinically effective, but structurally highly ..
  4. ncbi Adherence to guidelines by French psychiatrists in their real world of clinical practice
    Ludovic Samalin
    Centre Hospitalier Universitaire, Clermont Ferrand, France
    J Nerv Ment Dis 199:239-43. 2011
    ..Guidelines for treatment of bipolar disorder are not frequently used. French psychiatrists' age and practice type are the most important variables correlated to the level of use of guidelines...
  5. ncbi Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians
    Roy H Perlis
    Depression and Bipolar Clinical and Research Programs, Massachusetts General Hospital, Boston, MA 02114, USA
    Curr Med Res Opin 23:467-75. 2007
    ..The objective of this study was to assess the extent to which such guidelines are used in the treatment of bipolar disorder...
  6. ncbi Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry
    Konstantinos N Fountoulakis
    3rd Department of Psychiatry, School of Medicine, Aristotle University of Thessaloniki, 6 Odysseos str 1st Parodos Ampelonon str, Pylaia, Thessaloniki, Greece
    Eur Arch Psychiatry Clin Neurosci 262:1-48. 2012
    ..Combination therapy may improve the treatment outcome but it also carries more side-effect burden. Further research is necessary as well as the development of better guidelines and algorithms for the step-by-step rational treatment...
  7. ncbi Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder
    Alessio Squassina
    Department of Neuroscience BB Brodie, University of Cagliari, Cagliari, Italy
    Pharmacogenomics 12:1559-69. 2011
    ..Here, we present the results of an exploratory genome-wide scan followed by extended genotyping carried out on a sample of 204 Sardinian BD patients characterized for lithium response...
  8. pmc Functional genetic variation in the Rev-Erbα pathway and lithium response in the treatment of bipolar disorder
    M J McCarthy
    Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA
    Genes Brain Behav 10:852-61. 2011
    ..Our findings support a role for Rev-Erbα in the therapeutic mechanism of lithium and suggest that the interaction between Rev-Erbα and GSK3β may warrant further study...
  9. ncbi Pharmacotherapy for the treatment of acute bipolar II depression: current evidence
    Holly A Swartz
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    J Clin Psychiatry 72:356-66. 2011
    ..This review focuses on a critical examination of the evidence supporting the efficacy of treatments for acute depressive episodes in bipolar II disorder...
  10. ncbi Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis
    Michelle M Sidor
    Department of Psychiatry, University of Texas, Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9070, USA
    J Clin Psychiatry 72:156-67. 2011
    ..The current systematic review and meta-analyses reexamine the efficacy and safety of antidepressant use for the acute treatment of bipolar depression...
  11. ncbi Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
    ..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone...
  12. ncbi Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials
    John R Geddes
    Department of Psychiatry, University of Oxford, Warneford Hospital, UK
    Am J Psychiatry 161:217-22. 2004
    ..The authors sought to determine the efficacy and acceptability of lithium for relapse prevention in bipolar disorder...
  13. ncbi The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania
    Heinz Grunze
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstrasse 7, 80336 Munich, Germany
    World J Biol Psychiatry 4:5-13. 2003
    ..Key words: bipolar disorder, mania, acute treatment, evidence-based guidelines, pharmacotherapy, antipsychotics, mood stabiliser, electroconvulsive therapy...
  14. doi A successful effort to improve adherence to treatment guidelines for bipolar disorder
    Thomas E Smith
    New York State Psychiatric Institute, 1051 Riverside Dr, Unit 14, New York, NY 10032, USA
    Harv Rev Psychiatry 16:210-3. 2008
  15. ncbi Enhancing multiyear guideline concordance for bipolar disorder through collaborative care
    Mark S Bauer
    Harvard Medical School and the Center for Organization, Leadership, and Management Research, Boston VA Healthcare System, MA, USA
    Am J Psychiatry 166:1244-50. 2009
    ..In a multiregion effectiveness trial in veterans with bipolar disorder, the authors assessed the effects of a collaborative care model for this disorder on guideline concordance in care over a 3-year period...
  16. ncbi Predicting response to lithium in bipolar disorder: a critical review of pharmacogenetic studies
    Daniel J Smith
    Department of Psychological Medicine, School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK
    J Ment Health 19:142-56. 2010
    ..In recent years a number of pharmacogenetic studies have attempted to identify genetic variants which might be associated with response to lithium in bipolar patients...
  17. ncbi Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients
    Monika Dmitrzak-Weglarz
    Laboratory of Psychiatric Genetics, Department of Psychiatry, University of Medical Sciences, ul Szpitalna 27 33, 60 572 Poznan, Poland
    Pharmacogenomics 9:1595-603. 2008
    ..No association with lithium response was revealed with the polymorphism of NTRK2 gene, neither with interaction of BDNF and NTRK2 genes...
  18. ncbi Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism
    Mazda Adli
    Department of Psychiatry and Psychotherapy, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany
    Biol Psychiatry 62:1295-302. 2007
    ..This study investigates the association of the GSK3B -50T/C SNP and response to lithium augmentation in acutely depressed antidepressant nonresponders...
  19. pmc Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009
    Joseph Hayes
    Mental Health Sciences Unit, University College London, London, United Kingdom
    PLoS ONE 6:e28725. 2011
    ....
  20. ncbi Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD
    Naomi M Simon
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychopharmacol 24:512-20. 2004
    ..Our findings highlight the need for greater clinical guidance and treatment options for patients with bipolar disorder and comorbidity...
  21. ncbi Current management of bipolar affective disorder: is it reflective of the BAP guidelines?
    N Farrelly
    Harvard Bipolar Clinic and Research Program, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA 02114, USA
    J Psychopharmacol 20:128-31. 2006
    ..The BAP guidelines offer a practical and auditable basis for the short- and long-term treatment of bipolar affective disorder...
  22. ncbi Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder
    Takuya Masui
    Psychiatr Genet 16:49-50. 2006
    ..Our results suggested that the brain-derived neurotrophic factor Val66Met polymorphism might not greatly contribute to the efficacy of lithium in bipolar disorder...
  23. ncbi Effectiveness of adjunctive antidepressant treatment for bipolar depression
    Gary S Sachs
    Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 356:1711-22. 2007
    ..Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania...
  24. pmc Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior
    Maria A Oquendo
    Columbia University, New York State Psychiatric Institute, New York, USA
    Am J Psychiatry 168:1050-6. 2011
    ..The authors tested the hypothesis that lithium offers bipolar patients with a history of suicide attempt greater protection against suicidal behavior compared to valproate...
  25. ncbi Medicating mood with maintenance in mind: bipolar depression pharmacotherapy
    Gin S Malhi
    CADE Clinic, Department of Psychiatry, Royal North Shore Hospital, Sydney, Australia
    Bipolar Disord 11:55-76. 2009
    ..The purpose of this paper is to briefly review the evidence base for the pharmacotherapy of bipolar depression and to discuss the recommendations for its optimal management...
  26. ncbi Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy
    Janusz K Rybakowski
    Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
    J Psychopharmacol 26:368-73. 2012
    ..Possible aspects of these genes with regard to the mechanism of lithium activity and pathogenesis of bipolar mood disorder are discussed...
  27. ncbi Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression
    Mark A Frye
    Department of Psychiatry, Mayo Mood Clinic and Research Program, Mayo Clinic, 200 First St, S W, Rochester, MN 55901, USA
    Am J Psychiatry 166:164-72. 2009
    ..This study examined the correlates associated with treatment-emergent mania in patients receiving adjunctive antidepressant treatment for bipolar depression...
  28. ncbi A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder
    Takuya Masui
    Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita ku, Sapporo, 060 8638, Hokkaido, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 32:204-8. 2008
    ..We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings...
  29. ncbi Mood stabilizers increase prepulse inhibition in DBA/2NCrl mice
    Dorothy G Flood
    CNS Biology, Worldwide Discovery Research, Cephalon, Inc, 145 Brandywine Parkway, West Chester, PA 19380, USA
    Psychopharmacology (Berl) 205:369-77. 2009
    ..Lithium and several antiepileptic drugs have mood-stabilizing effects in bipolar disorder and schizophrenia. Both disorders are characterized by deficits in prepulse inhibition (PPI) of the acoustic startle response...
  30. ncbi A clinician's guide to monitoring kidney function in lithium-treated patients
    James W Jefferson
    Department of Psychiatry, Healthcare Technology Systems, Inc, 7617 Mineral Point Rd, Ste 300, Madison, WI 53717, USA
    J Clin Psychiatry 71:1153-7. 2010
    ..This overview clarifies those practical aspects of monitoring that are often overlooked or misunderstood...
  31. ncbi Is lithium in a class of its own? A brief profile of its clinical use
    Gin S Malhi
    Discipline of Psychological Medicine, University of Sydney, Australia
    Aust N Z J Psychiatry 43:1096-104. 2009
    ..Arguably, lithium is the only true mood stabilizer and because of its unique properties is in a class of its own...
  32. ncbi The mechanism of lithium action: state of the art, ten years later
    A Shaldubina
    Stanley Center for Bipolar Research, Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheba, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 25:855-66. 2001
    ..Biochemical and clinical experiments are necessary to determine the key mechanism of lithium efficacy in treatment and prophylaxis of affective disorders...
  33. ncbi Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892 3711, USA
    Neuropsychopharmacology 32:2173-83. 2007
    ..By associating the behavioral effects of lithium with beta-catenin levels, these data suggest that increasing beta-catenin might be a novel therapeutic strategy for mood disorders...
  34. pmc Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder
    Jess G Fiedorowicz
    Department of Psychiatry, Roy J and Lucille A Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA
    Ann Clin Psychiatry 20:131-7. 2008
    ..We hypothesized outpatients with bipolar disorder would exhibit excess cardiovascular risk factors, particularly among prevalent users of the second-generation antipsychotics associated with weight gain and valproic acid derivatives...
  35. pmc Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium
    Lara C Foland
    Laboratory of Neuroimaging, Department of Neurology, University of California, UCLA School of Medicine, Los Angeles, California, USA
    Neuroreport 19:221-4. 2008
    ..Our findings may help to explain previous inconsistencies in the bipolar literature...
  36. ncbi Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder
    Shinsuke Washizuka
    Laboratory for Molecular Dynamics of Mental Disorders, Brain Science Institute, RIKEN, Saitama, Japan
    Int J Neuropsychopharmacol 6:421-4. 2003
    ..05). Our findings suggest that the mtDNA 10398 polymorphism might be related to maintenance lithium treatment response...
  37. ncbi Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    Richard H Weisler
    Department of Psychiatry and Behavioral Sciences, Duke University, 700 Spring Forest, Suite 125, Raleigh, NC 27609, USA
    J Clin Psychiatry 66:323-30. 2005
    ..In the present study, we further evaluated the efficacy and safety of monotherapy with beaded, extended-release carbamazepine capsules (ERC-CBZ) in patients with bipolar I disorder experiencing manic or mixed episodes...
  38. ncbi Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications
    Ho Jun Seo
    Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, South Korea
    Clin Neuropharmacol 34:39-47. 2011
    ..We also inform clinicians of practical issues in safety and tolerability in the use of lamotrigine in the treatment of bipolar disorders...
  39. ncbi Association study of the glycogen synthase kinase-3beta gene polymorphism with prophylactic lithium response in bipolar patients
    Aleksandra Szczepankiewicz
    Laboratory of Psychiatric Genetics, Department of Psychiatry, Poznan University of Medical Sciences, Poland
    World J Biol Psychiatry 7:158-61. 2006
    ..The patients were delineated as excellent responders, partial responders and non-responders to lithium. The results obtained suggest that this polymorphism may not be related to the degree of prophylactic lithium response...
  40. ncbi Medication prescribing patterns for patients with bipolar I disorder in hospital settings: adherence to published practice guidelines
    P Z Lim
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Bipolar Disord 3:165-73. 2001
    ..CONCLUSIONS: Results suggest that a substantial proportion of patients with bipolar I disorder are discharged from hospitals on medications not generally recommended by current practice guidelines...
  41. ncbi Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study
    Lori L Altshuler
    Department of Psychiatry, Veterans Affairs Greater Los Angeles Healthcare System, West Los Angeles Healthcare Center, Los Angeles, CA, USA
    J Clin Psychiatry 70:450-7. 2009
    ..To assess long-term outcome in bipolar disorder, subjects were prospectively followed after receiving acute treatment for bipolar depression...
  42. ncbi Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6)
    Rasmus W Licht
    Mood Disorders Research Unit, Aarhus University Hospital, Risskov, Risskov, Denmark
    Bipolar Disord 12:483-93. 2010
    ..Here, we directly compared lamotrigine to lithium under conditions similar to clinical routine conditions...
  43. ncbi A control study of the cutaneous side effects of chronic lithium therapy
    H H Chan
    Division of Dermatology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, 9 F Clinical Science Building, Prince of Wales Hospital, Shatin, Hong Kong
    J Affect Disord 57:107-13. 2000
    ..To assess the nature and prevalence of skin disorders among psychiatric patients on chronic lithium therapy and to compare them with patients on other psychotropic medications...
  44. ncbi Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study
    Lars Vedel Kessing
    Psychiatric Center Copenhagen, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Br J Psychiatry 199:57-63. 2011
    ..Valproate is one of the most used mood stabilisers for bipolar disorder, although the evidence for the effectiveness of valproate is sparse...
  45. ncbi Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules
    H Sang
    Department of Cell Biology and Genetics, College of Life Science, Peking University, Beijing 100871, China
    Neurosci Lett 312:141-4. 2001
    ..The bundles induced by GSK-3beta phosphorylated tau were sensitive to colchicine, and could be reversed by the addition of LiCl, an inhibitor of GSK-3beta...
  46. pmc Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program
    David J Miklowitz
    Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
    Arch Gen Psychiatry 64:419-26. 2007
    ..Psychosocial interventions have been shown to enhance pharmacotherapy outcomes in bipolar disorder...
  47. ncbi Differential clinical characteristics, medication usage, and treatment response of bipolar disorder in the US versus The Netherlands and Germany
    Robert M Post
    Bipolar Collaborative Network, 5415 W Cedar Lane, Suite 201 B, Bethesda, MD 20814, USA
    Int Clin Psychopharmacol 26:96-106. 2011
    ....
  48. ncbi Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study
    N Kleindienst
    Psychiatric Hospital of the University of Munich, Germany
    Neuropsychobiology 42:2-10. 2000
    ..Hence, treatment alternatives to lithium are desirable for the majority of bipolar patients...
  49. ncbi Nuclear receptor rev-erb-{alpha} circadian gene variants and lithium carbonate prophylaxis in bipolar affective disorder
    Sara Campos-de-Sousa
    MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King s College London, UK
    J Biol Rhythms 25:132-7. 2010
    ..18-10.76). The results of this study may help to identify potential biological markers that can serve to predict the response of bipolar affective disorder patients to treatment, improving treatment efficacy...
  50. ncbi Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder
    Hadine Joffe
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Biol Psychiatry 59:1078-86. 2006
    ..The development of PCOS features after initiation of valproate was therefore examined in women with bipolar disorder using a standardized definition of PCOS...
  51. ncbi Lithium: clinical considerations in internal medicine
    Marlene P Freeman
    Women s Mental Health Program, Department of Psychiatry, University of Arizona College of Medicine, Tucson, AZ 85724 5002, USA
    Am J Med 119:478-81. 2006
    ..Important laboratory monitoring guidelines are included in this review. Lithium remains an important intervention for the treatment of mood disorders...
  52. ncbi State of the art: treatment of bipolar disorders
    Emanuel Severus
    Department of Psychiatry, University of Munich, Munich, Bavaria, Germany
    CNS Neurosci Ther 18:214-8. 2012
    ..In addition new methodological approaches regarding the proof of effectiveness in clinical practice are urgently needed...
  53. ncbi Lithium differentially affects clock gene expression in serum-shocked NIH-3T3 cells
    Teresa M Osland
    Dr Einar Martens Research Group for Biological Psychiatry and Bergen Mental Health Research Center, Department of Clinical Medicine, University of Bergen, Bergen, Norway
    J Psychopharmacol 25:924-33. 2011
    ..Taken together, these effects on clock gene expression may be relevant for the effects of lithium on biological rhythms and could also give new leads to further explore its mood-stabilizing actions in the treatment of bipolar disorder...
  54. ncbi Quality of care in a Medicaid population with bipolar I disorder
    Alisa B Busch
    Alcohol and Drug Abuse Treatment Program, McLean Hospital, 115 Mill St, Belmont, MA 02478, USA
    Psychiatr Serv 58:848-54. 2007
    ..This study examined whether presenting diagnosis and treatment in intensive settings (hospitalization, partial hospitalization, or residential programs) are correlated with the subsequent treatment of bipolar I disorder...
  55. ncbi World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression
    Heinz Grunze
    Department of Psychiatry, Ludwig Maximilians University, Nussbaumstrasse 7, 80336 Munich, Germany
    World J Biol Psychiatry 3:115-24. 2002
    ..As these guidelines are intended for clinical use, the scientific evidence was not only graded, but also commented on by the experts of the task force to ensure practicability...
  56. ncbi Gabapentin augmentation therapy in bipolar depression
    Po W Wang
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5723, USA
    Bipolar Disord 4:296-301. 2002
    ..Gabapentin (GBP) may be useful in bipolar disorders, including as adjunctive therapy for bipolar depression, although controlled studies suggest inefficacy as primary treatment for mania or treatment-resistant rapid cycling...
  57. ncbi The collaborative practice model for bipolar disorder: design and implementation in a multi-site randomized controlled trial
    M S Bauer
    Veterans Affairs Medical Center, Brown University, Providence, Rhode Island 02908 4799, USA
    Bipolar Disord 3:233-44. 2001
    ..The BDP provides an example of a multi-faceted collaborative practice model that can be manualized and implemented across multiple sites in a randomized controlled trial...
  58. ncbi Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder
    Dan Chisholm
    Department of Health System Financing, Evidence and Information for Policy EIP, World Health Organization, 1211 Geneva, Switzerland
    Br J Psychiatry 187:559-67. 2005
    ..Bipolar disorder has been ranked seventh among the worldwide causes of non-fatal disease burden...
  59. pmc The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment
    Thomas G Schulze
    Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 3719, USA
    Neuropsychobiology 62:72-8. 2010
    ..A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts...
  60. ncbi Two generations of mood stabilizers
    Janusz K Rybakowski
    Int J Neuropsychopharmacol 10:709-11. 2007
  61. ncbi Lithium: still a cornerstone in the long-term treatment in bipolar disorder?
    Alessandra M A Nivoli
    Bipolar Disorder Program, IDIBAPS, CIBERSAM, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Neuropsychobiology 62:27-35. 2010
    ..Despite its worldwide clinical use, the effectiveness of lithium has been questioned. The aim of this work is to critically review the available data on randomized controlled trials (RCTs) concerning long-term lithium treatment...
  62. ncbi Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients
    C Schumann
    Department of Psychiatry, University of Vienna, Austria
    Psychiatry Res 89:247-57. 1999
    ..Our findings confirmed non-adherence as a major problem in the effectiveness of lithium prophylaxis. The authors recommend prospective investigations of attitudes and the impact of psychoeducation on long-term adherence...
  63. ncbi Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?
    T A Ketter
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
    Acta Psychiatr Scand 123:175-89. 2011
    ..To compare bipolar treatment interventions, using number needed to treat (NNT) and number needed to harm (NNH)...
  64. ncbi Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD
    Lauren B Marangell
    Mood Disorders Center, Menninger Department of Psychiatry, Baylor College of Medicine and South Central Mental Illness Research and Education Core, Department of Veterans Affairs, Houston, Tex, USA
    J Clin Psychiatry 69:916-22. 2008
    ....
  65. ncbi The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder
    W Greil
    Psychiatric Hospital, University of Munich, Germany
    Int Clin Psychopharmacol 14:277-81. 1999
    ..Analyses in patients without psychotropic comedication indicate that the superiority of lithium is not the result of carbamazepine reducing plasma levels of concomitant drugs...
  66. ncbi Lithium-associated hyperparathyroidism: report of four cases and review of the literature
    Auryan Szalat
    Endocrinology and Metabolism Service Department of Surgery, Hadassah Hebrew University Medical School, Jerusalem, Israel
    Eur J Endocrinol 160:317-23. 2009
    ..Lithium-associated hyperparathyroidism (LAH) was first described in 1973 but many issues remain in question regarding the pathophysiology as well as the appropriate management of this condition...
  67. ncbi Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety
    Etienne Marc Grandjean
    Phidalsa Institute for Clinical Investigation, Geneva, Switzerland
    CNS Drugs 23:397-418. 2009
    ....
  68. ncbi Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009
    Jessica Pillarella
    Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA
    Psychiatr Serv 63:83-6. 2012
    ..S. Food and Drug Administration's approval in 2000 of olanzapine for use in treating acute manic episodes of bipolar disorder...
  69. ncbi Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms
    Alessandro Serretti
    Institute of Psychiatry, University of Bologna, Bologna, Italy
    Neuropsychobiology 62:61-71. 2010
    ..Moreover, the pharmacogenetics reports that are not strictly associated with the mechanisms that are thought to be acutely and chronically elicited by lithium will be included in the final part of the paper...
  70. ncbi A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder
    K Soares-Weiser
    Centre for Reviews and Dissemination, University of York, UK
    Health Technol Assess 11:iii-iv, ix-206. 2007
    ..To determine the clinical effectiveness and cost-effectiveness of pharmacological and/or psychosocial interventions for the prevention of relapse in people with bipolar disorder...
  71. ncbi The prophylactic effect of long-term lithium administration in bipolar patients entering treatment in the 1970s and 1980s
    J K Rybakowski
    Department of Adult Psychiatry, University of Medical Sciences, Poznan, Poland
    Bipolar Disord 3:63-7. 2001
    ....
  72. ncbi Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression
    Jing Du
    Laboratory of Molecular Pathophysiology, National Institutes of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 4405, USA
    Ann N Y Acad Sci 1003:378-80. 2003
    ....
  73. pmc Bipolar-I patient characteristics associated with differences in antimanic medication prescribing
    Alisa B Busch
    McLean Hospital, Belmont, MA, USA
    Psychopharmacol Bull 42:35-49. 2009
    ..We studied the association between patient characteristics and patient-reported antimanic medication use upon entry in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)...
  74. ncbi Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials
    S Beynon
    Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK
    J Psychopharmacol 23:574-91. 2009
    ..Despite widespread use in clinical practice, there is little evidence to support the efficacy of combination therapy...
  75. ncbi Effects of mood stabilizers on the disruption of prepulse inhibition induced by apomorphine or dizocilpine in mice
    Kenta Umeda
    Department of Neuropharmacology Faculty of Pharmaceutical Sciences, Fukuoka University, 8 19 1 Nanakuma, Jonan ku, Fukuoka 814 0180, Japan
    Eur J Pharmacol 553:157-62. 2006
    ..3 mg/kg, s.c.), lithium carbonate exacerbated the dizocilpine-induced disruption. These results suggest that valproate, carbamazepine and lithium carbonate reverse the disruption of prepulse inhibition through the dopaminergic system...
  76. ncbi Glucocorticoid receptor polymorphism is associated with lithium response in bipolar patients
    Aleksandra Szczepankiewicz
    Department of Psychiatry, Poznan University of Medical Sciences, Poland
    Neuro Endocrinol Lett 32:545-51. 2011
    ..As glucocorticoid receptor may be possibly related to lithium action we aimed to investigate variation in the GR gene in association with response to lithium treatment in Polish population of bipolar patients...
  77. ncbi Impact of an educational program on the management of bipolar disorder in primary care
    Frederic Rouillon
    CMME, Centre Hospitalier Sainte Anne, Paris Inserm, Paris
    Bipolar Disord 13:318-22. 2011
    ..Therefore, we conducted a survey among general practitioners to evaluate the impact of the Bipolact Educational Program on the diagnosis and treatment of bipolar disorder...
  78. ncbi A lithium clinic for bipolar patients: 2-year outcome of the first 148 patients
    R W Licht
    Mood Disorders Research Unit, Aarhus University Psychiatric Hospital, Skovagervej 2, DK-8240 Risskov, Denmark
    Acta Psychiatr Scand 104:387-90. 2001
    ..Better long-term treatment results for bipolar patients depend on both the development of more effective mood stabilizing drugs or drug combinations and the improvement of patients' adherence to treatment...
  79. ncbi Evolving methodologies in bipolar disorder maintenance research
    J R Calabrese
    Mood Disorders Program, Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA
    Br J Psychiatry Suppl 41:s157-63. 2001
    ..Comparisons with the early bipolar disorder maintenance studies indicate that the methodologies of recent trials have evolved substantially...
  80. ncbi Mania associated with antidepressant treatment: comprehensive meta-analytic review
    L Tondo
    Department of Psychiatry and Neuroscience Program, Harvard Medical School and McLean Division of Massachusetts General Hospital, Boston, MA, USA
    Acta Psychiatr Scand 121:404-14. 2010
    ..To review available data pertaining to risk of mania-hypomania among bipolar (BPD) and major depressive disorder (MDD) patients with vs. without exposure to antidepressant drugs (ADs) and consider effects of mood stabilizers...
  81. ncbi Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide
    Lars Søndergård
    Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark
    Bipolar Disord 10:87-94. 2008
    ..This study investigated the association between continued mood-stabilizing treatment (lithium and anticonvulsants) in bipolar disorder (BD) and the risk of suicide...
  82. ncbi Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
    G M Goodwin
    University Department of Psychiatry, Warneford Hospital, Oxford, UK
    J Psychopharmacol 23:346-88. 2009
    ..The strength of supporting evidence was rated. The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use of medicines in treatment of episodes, relapse prevention and stopping treatment...
  83. ncbi A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group
    C L Bowden
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, 78284 7792, USA
    Arch Gen Psychiatry 57:481-9. 2000
    ..This study compared the efficacy of divalproex, lithium, and placebo as prophylactic therapy...
  84. ncbi Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons
    Anita C Hall
    Department of Biological Sciences, Imperial College of Science, Technology and Medicine, London SW7 2AY
    Mol Cell Neurosci 20:257-70. 2002
    ..Lithium directly inhibits GSK-3beta in contrast to VPA, which inhibits GSK-3beta indirectly by an as-yet-unknown pathway. These findings may have important implications for the development of new strategies to treat bipolar disorders...
  85. ncbi A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes
    Terence A Ketter
    Stanford University School of Medicine, Stanford, California 94305 5723, USA
    J Clin Psychiatry 65:668-73. 2004
    ..We evaluated open-label monotherapy with beaded extended-release carbamazepine capsules (ERC-CBZ; SPD417) as continuation and short-term maintenance therapy in bipolar disorder patients with manic and mixed episodes...
  86. ncbi Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates
    P KuLhara
    Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
    J Affect Disord 54:87-96. 1999
    ..Also, role of psychosocial factors in influencing the outcome is unclear...
  87. ncbi The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS
    G Chen
    Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Neurochem 72:879-82. 1999
    ..These novel findings represent the first report of medication-induced increases in CNS bcl-2 levels and may have implications not only for mood disorders, but also for long-term treatment of various neurodegenerative disorders...
  88. ncbi Search for a common mechanism of mood stabilizers
    Adrian J Harwood
    MRC Laboratory for Molecular Cell Biology, University College London, Gower St, London, WC1E 6BT, UK
    Biochem Pharmacol 66:179-89. 2003
    ..Despite these intriguing observations, it remains unclear how changes in inositol signaling underlie the origins of bipolar disorder...
  89. ncbi The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients
    Aleksandra Szczepankiewicz
    Department of Pediatric Pulmonology, Allergy and Clinical Immunology, IIIrd Department of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland
    Hum Psychopharmacol 24:287-91. 2009
    ..The results are discussed in light of our previous studies on FYN gene in bipolar illness and BDNF gene in lithium response...
  90. ncbi Divalproex in the treatment of bipolar depression: a placebo-controlled study
    Lori L Davis
    Veteran s Affairs Medical Center 151, 3701 Loop Road East, Tuscaloosa, AL 35404, USA
    J Affect Disord 85:259-66. 2005
    ..Thus, the potential antidepressant efficacy of mood stabilizers, such as divalproex, which is an effective treatment for the manic phase of bipolar disorder, is of considerable interest...
  91. ncbi Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study
    Eduard Vieta
    Bipolar Disorders Program, Hospital Clinic, University of Barcelona IDIBAPS, Barcelona, Spain
    J Affect Disord 106:63-72. 2008
    ....
  92. ncbi Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study
    J M Haro
    Sant Joan de Deu SSM, Fundació Sant Joan de Déu, St Boi de Llobregat, Barcelona, Spain
    Acta Psychiatr Scand 113:112-20. 2006
    ..To describe patients included in the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study and to assess and clinically validate the presence of clinical subtypes of patients with acute mania...
  93. ncbi Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial
    Dennis A Revicki
    Center for Health Outcomes Research, MEDTAP International, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA
    J Affect Disord 86:183-93. 2005
    ..The clinical, quality of life (QOL), and medical cost outcomes of treatment with divalproex were compared with lithium in patients with bipolar I disorder over 1 year...
  94. ncbi Lithium specificity in bipolar illness: a classic agent for the classic disorder
    Samuel Gershon
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Bipolar Disord 11:34-44. 2009
    ..We demonstrate that lithium possesses significant clinical and therapeutic efficacy that is very individual and thus remains the treatment of choice for bipolar disorder when used specifically in select patients...
  95. ncbi A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders
    Jan Scott
    Division of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, UK, and Stanley Center for Bipolar Disorders, Hospital Clinic University of Barcelona, IDIBAPS, Spain
    Int J Neuropsychopharmacol 10:123-9. 2007
    ....
  96. ncbi The role of hippocampus in the pathophysiology of bipolar disorder
    Benicio N Frey
    Bipolar Disorders Program and Laboratory of Molecular Psychiatry, Hospital de Clinicas de Porto Alegre, Rio Grande do Sul, Brazil
    Behav Pharmacol 18:419-30. 2007
    ..In conclusion, the available evidence suggests that the hippocampus plays an important role in the pathophysiology of BD...
  97. ncbi Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder
    Robert L Findling
    Department of Psychiatry, Case Western Reserve University, and the University Hospitals of Cleveland, Cleveland, Ohio 44106 5080, USA
    J Clin Psychiatry 68:781-8. 2007
    ..To determine if divalproex sodium was superior to placebo in the treatment of symptomatic youths who suffer from a bipolar spectrum disorder and who also have a parent with a diagnosis of a bipolar illness...
  98. pmc Prefrontal gray matter increases in healthy individuals after lithium treatment: a voxel-based morphometry study
    E Serap Monkul
    Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
    Neurosci Lett 429:7-11. 2007
    ..Whether these changes are mediated by neurotrophic/neuroprotective or osmotic effects remains unknown...
  99. ncbi Evolving trends in the long-term treatment of bipolar disorder
    Eduard Vieta
    Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
    World J Biol Psychiatry 8:4-11. 2007
    ..The role of psychoeducation in improving adherence to medication in long-term treatment and overall patient outcomes is also crucial...
  100. ncbi Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population
    Jeff J Guo
    College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH, USA
    Value Health 11:416-23. 2008
    ....
  101. ncbi Pharmacotherapy of bipolar depression: an update
    Michael E Thase
    University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213 2593, USA
    Curr Psychiatry Rep 8:478-88. 2006
    ..Antidepressants--particularly selective serotonin reuptake inhibitors and bupropion--are indicated when mood stabilizers are ineffective and for "breakthrough" depressions...

Research Grants63

  1. Bipolar Statistical Summit:Methodologies to Advance Long Term Intervention Trials
    Charles Bowden; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  2. Course and Morbidity in Bipolar I Disorder
    Ross Baldessarini; Fiscal Year: 2006
    ..Anticipated findings should contribute important new information to guide effective interventions and allocation of increasingly limited treatment resources for BPD patients. ..
  3. Antidepressant discontinuation effects
    Ross Baldessarini; Fiscal Year: 2007
    ..bipolar depressive subjects separately. The findings expected should contribute to improved safety of antidepressant treatment and reduced morbid and mortal risks following its discontinuation. [unreadable] [unreadable]..
  4. Divalproex sodium and Risperidone in Pediatric Bipolar Disorder
    Mani Pavuluri; Fiscal Year: 2007
    ..During five years, 40 outpatient subjects with PBD manic or mixed episodes, ages 8-17 years, referred to the UI Pediatric Mood Disorder Clinic will be recruited. ..
  5. Neuroimaging of Children at Risk for Biopolar Disorder
    Kiki Chang; Fiscal Year: 2006
    ..Chang plans to become an independent investigator in the field of pediatric BD and thus contributing to the current knowledge of the neurobiology and development of BD. ..
  6. Topiramate for Co-occurring Cannabis Use and Bipolar Disorders in Adolescents
    Melissa Delbello; Fiscal Year: 2008
    ..The preliminary data from this projectwill inform and guide the design of future larger, more definitive, controlled studies of topiramate as a treatment for adolescent substance use disorders. ..
  7. Brain Abnormalities in Adolescent Bipolar Disorder
    Melissa Delbello; Fiscal Year: 2006
    ..The research conducted will advance our understanding of the neurophysiology of BPD. ..
  8. TREATMENT OF EARLY ONSET SCHIZOPHRENIA SPECTRUM (TEOSS)
    Robert Findling; Fiscal Year: 2005
    ..This study will provide information about the comparative effectiveness of the most commonly used and representative antipsychotic drugs in youth with schizophrenia spectrum disorders. ..
  9. ADJUNCTIVE ACUPUNCTURE TO TREAT BIPOLAR DEPRESSION
    PATRICIA SUPPES; Fiscal Year: 2002
    ..Should acupuncture demonstrate efficacy in the treatment of bipolar disorder, further studies will be proposed to evaluate its utility for maintenance and prevention. ..
  10. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  11. Pramipexole in Treatment-Resistant Depression
    Roy Perlis; Fiscal Year: 2007
    ..The proposed investigation and training program will provide critical skills, experience and data to aid the candidate in writing an R01 and becoming an independent investigator. ..
  12. Acute Treatment of Bipolar II Depression
    PATRICIA SUPPES; Fiscal Year: 2005
    ..This pilot study will provide data addressing the aims and sample size needed for a full-scale intervention trial. ..
  13. Bipolar Disorder & Alcohol Abuse Comorbidity
    Mark Frye; Fiscal Year: 2006
    ..This naturalistic follow-up period may identify preliminary neurobiological factors associated with relapse and provide direction for further controlled interventional study. ..
  14. Divalproex and Placebo, Lithium, or Quetiapine for Mania
    Trisha Suppes; Fiscal Year: 2008
    ..abstract_text> ..
  15. Treatment of Early Age Mania
    Karen Wagner; Fiscal Year: 2008
    ..The chief study statistician, Dr. Satish lyengar is subcontracted to the coordinating site at Washington U in St. Louis and Dr. Philip Lavori is a major consultant for statistical analyses. [unreadable] [unreadable]..
  16. Stepped Pharmacotherapy for Aggressive Youth with ADHD
    JOSEPH BLADER; Fiscal Year: 2006
    ..The proposed program will therefore culminate in the awardee's competence as a well-rounded clinical scientist focused on the complex treatment needs of youth with severe behavior disorders. ..
  17. Divalproex Sodium/Placebo In Child/Adolesent Autism
    Eric Hollander; Fiscal Year: 2003
    ....
  18. Comparative Effectiveness Study for Bipolar Disorder
    Andrew A Nierenberg; Fiscal Year: 2010
    ..The two treatments will be the second generation antipsychotic mood stabilizer quetiapine and the classic mood stabilizer lithium. In addition to quetiapine or lithium, participants can be treated with other medications as needed. ..
  19. PI and Wnt Signaling in Postmortem Brain of Biopolar and Schizophrenia Subjects
    Ghanshyam N Pandey; Fiscal Year: 2011
    ..This may eventually lead to i better understanding of the pathophysiology of BP or SZ illnesses and may aid in the development of more appropriate therapeutic agents for the treatment of these disorders. ..
  20. Antimanic Use During Pregnancy
    Katherine L Wisner; Fiscal Year: 2010
    ..No such PK data are currently available. ..
  21. Identification and Therapy of Postpartum Depression
    Katherine L Wisner; Fiscal Year: 2010
    ..We have developed a multi-disciplinary team with expertise in clinical research with depressed and minority women and health services to address these needs. ..
  22. FLUOXETINE IN PEDIATRIC BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2008
    ..Abstract Not Provided. ..
  23. Estrogen Use in Protection from Cognitive Decline
    Natalie L Rasgon; Fiscal Year: 2010
    ..abstract_text> ..
  24. Bipolar Disorder, Subjectivity and Treatment Adherence
    Martha Sajatovic; Fiscal Year: 2007
    ..abstract_text> ..
  25. TREATMENT OF SSRI RESISTANT DEPRESSION IN ADOLESCENTS
    Karen Wagner; Fiscal Year: 2006
    ..This site is based in Pittsburgh, which also serves as the Data Coordinating Center for the study [unreadable] [unreadable]..
  26. PHYSIOLOGY OF ESTROGEN'S MOOD EFFECT IN MENOPAUSAL WOMEN
    Hadine Joffe; Fiscal Year: 2007
    ..Such training will lay the foundation for a career of clinical investigation into the physiology of perimenopausal depression and the impact of hot flushes on sleep, mood, and quality-of-life. ..
  27. Greater New York Autism Research Center of Excellence
    Joseph Buxbaum; Fiscal Year: 2007
    ..Core B: Clinical Core; Core C: Data Management and Statistics Core; Core D: Information Transfer Core. ..
  28. Endocrine Function and Mood in Bipolar Disorder
    Natalie Rasgon; Fiscal Year: 2008
    ..abstract_text> ..
  29. S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    George Papakostas; Fiscal Year: 2008
    ..It is hoped that this project award will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator in this area. ..
  30. Postpartum Depression: Omega-3 FA vs Placebo
    Marlene Freeman; Fiscal Year: 2006
    ..These doses should provide an adequate test of the efficacy of omega-3 fatty acids while being safe for the mother and breastfeeding baby. ..
  31. FAMILY PSYCHOPATHOLOGY IN CHILD BIPOLARITY
    Barbara Geller; Fiscal Year: 2004
    ..Establishing high familial aggregation of bipolar disorders in relatives of PEA-BP probands will provide the basis for future genetic and genetic-environment interaction studies. ..
  32. ANTIDEPRESSANT USE DURING PREGNANCY
    Katherine Wisner; Fiscal Year: 2004
    ..Data from this investigation will increase our sophistication in making risk-benefit decisions during pregnancy. ..
  33. Combination Therapy in Bipolar Rapid Cycling
    Joseph Calabrese; Fiscal Year: 2004
    ....
  34. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  35. PEDIATRIC BIPOLAR COLLABORATIVE MOOD STABILZER TRAIL
    Robert Findling; Fiscal Year: 2003
    ..Lastly, this trial will provide descriptive information on the stability of acute phase response to monotherapy over a 16 week continuation phase. ..
  36. RELAPSE OF BIPOLAR DISORDER DURING PREGNANCY
    Adele Viguera; Fiscal Year: 2003
    ..abstract_text> ..
  37. PHARMACOTHERAPY OF ADOLESCENT BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2002
    ..When untreated, adolescent-onset BDD appears to often interfere with the developmental tasks of adolescence, to persist, and to cause substantial morbidity through out the life span. ..
  38. ERT, DEPRESSION AND COGNITION IN POSTMENOPAUSAL WOMEN
    Natalie Rasgon; Fiscal Year: 2002
    ..antidepressant alone. This research will be the foundation for a future investigation of pathophysiology of reproductive-related mood disorders. ..
  39. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  40. Pharmacotherapy for Minor Depression
    Andrew Nierenberg; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  41. PREVENTION OF RECURRENT POSTPARTUM MAJOR DEPRESSION
    Katherine Wisner; Fiscal Year: 2005
    ..Maternal MD, an exposure that clearly has a negative impact upon several aspects of child development, also will be considered as an exposure with effects on child outcomes. ..
  42. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  43. Cognitive-Behavioral Therapy for Pathological Gambling
    Jon Grant; Fiscal Year: 2008
    ..This award would provide me with the necessary background for further studies in the treatment of pathological gambling and the training for an independent patient-oriented research career. ..
  44. Training in Psychopharmacology and Outcomes Research
    Eric Hollander; Fiscal Year: 2008
    ..of Medicine of Medicine of Medicine of Medicine of Medicine of Medicine format shown below. Role on ..
  45. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  46. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  47. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  48. Long-term antidepressant outcome in bipolar depression
    NASSIR GHAEMI; Fiscal Year: 2005
    ..In this process, the applicant will develop competence to lead independent studies of the long-term treatment of bipolar disorder as a principal investigator. ..
  49. PKC and Cellular Signaling in the Suicide Brain
    Ghanshyam Pandey; Fiscal Year: 2009
    ..This knowledge may aid in developing better therapeutic strategies for the treatment of suicidal behavior. ..
  50. Bipolar Disorder in Pregnancy: Predictors of Morbidity
    DONALD NEWPORT; Fiscal Year: 2009
    ..Furthermore, the novel PK data will expand our understanding of prenatal drug metabolism, and the project will establish a cohort of children of women with BPD with detailed prospective prenatal histories. ..
  51. Bipolar II Depression: Lithium, SSRI or the Combination
    Susan L McElroy; Fiscal Year: 2010
    ..We also hypothesize that the frequency of side effects will be significantly less in patients on SSRI monotherapy. Thus, secondary aims include assessment of patient satisfaction, which may affect compliance in the clinical setting. ..
  52. Norepinephrine and Impulsivity
    Alan Swann; Fiscal Year: 2009
    ..The results of these experiments may suggest means for monitoring risk for impulsive behavior and for a rational treatment schema for impulsivity. ..
  53. RESEARCH TRAINING IN JUVENILE BIPOLAR DISORDER
    Pablo Davanzo; Fiscal Year: 2002
    ..In addition to furthering the candidate's transition to independent research, the proposed study would also contribute to our knowledge of pharmacological treatment and possible neurobiological markers of juvenile bipolar disorder. ..
  54. BUPROPION AS AN ADJUNCT TO THE NICOTINE PATCH PLUS CBT
    Maurizio Fava; Fiscal Year: 2003
    ....
  55. Anterior limbic network dysfunction in bipolar disorder
    Stephen Strakowski; Fiscal Year: 2008
    ..Finally, this work will provide a neurophysiologic substrate to inform additional investigations aimed at identify mechanisms underlying anterior limbic dysfunction both in human and animal models. ..
  56. MOLECULAR NEUROBIOLOGY OF DEPRESSION
    Richard Shelton; Fiscal Year: 2003
    ..Develop further expertise in basic molecular biological methods; 2. Develop new projects oriented to future funding opportunities; and 3. Continue to mentor the next generation of investigators. ..
  57. NMR AND FLUORESCENCE STUDY OF LI+ INTERACTIONS IN CELLS
    Duarte Mota de Freitas; Fiscal Year: 2003
    ..abstract_text> ..
  58. PGP Regulation of Antipsychotic Exposure and Effects
    C Devane; Fiscal Year: 2008
    ..The results of this research will provide support for translational studies in humans to refine treatment guidelines for the use of this class of medications in severely mentally ill patients. ..
  59. Development Psychopharmacology
    DONALD NEWPORT; Fiscal Year: 2005
    ..These study procedures will furthermore be applicable to future research investigating other classes of psychotropic medications. ..
  60. TREATMENT AND OUTCOME OF EARLY ONSET BIPOLAR DISORDER
    Vivian Kafantaris; Fiscal Year: 2005
    ..In addition, a lower risk of TD with the novel antipsychotics may alter the risk: benefit ratio in favor of longer-term antipsychotic treatment. ..
  61. TRAINING IN FUNCTIONAL IMAGING AND ALCOHOL WITHDRAWAL
    DONALD MYRICK; Fiscal Year: 2004
    ....
  62. Family Check-Up for Depression Prevention
    LISA UEBELACKER; Fiscal Year: 2007
    ..Secondary outcome variables include incidence of major depressive episodes and change in family functioning. The purpose of Phase 2 is to gain an estimate of effect size for a larger randomized controlled trial. ..
  63. Sensory Gating in Schizophrenia: Multiple Measures
    Julie Patterson; Fiscal Year: 2004
    ....